Antimicrobial susceptibilities of group B streptococci isolated between 1992 and 1996 from patients with bacteremia or meningitis.
about
Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis.Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines.Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzymeHeterogeneity of genotype-phenotype correlation among macrolide-resistant Streptococcus agalactiae isolates.Streptococcus agalactiae in adults at Chiang Mai University Hospital: a retrospective study.Mechanisms of macrolide resistance in clinical group B streptococci isolated in France.High incidence of erythromycin resistance among clinical isolates of Streptococcus agalactiae in Taiwan.Prevalence and mechanisms of macrolide resistance in invasive and noninvasive group B streptococcus isolates from Ontario, Canada.Antimicrobial susceptibilities of group B streptococci isolated from patients with invasive disease: 10-year perspective.Distribution of serotypes and antimicrobial resistance genes among Streptococcus agalactiae isolates from bovine and human hosts.Group B Streptococcus prophylaxis in patients who report a penicillin allergy: a follow-up study.Erythromycin and clindamycin resistance and telithromycin susceptibility in Streptococcus agalactiae.Genetic basis of antibiotic resistance in Streptococcus agalactiae strains isolated in a French hospital.A serotype V clone is predominant among erythromycin-resistant Streptococcus agalactiae isolates in a southwestern region of Germany.Group B streptococcal conjugate vaccines.Telithromycin susceptibility and genomic diversity of macrolide-resistant serotype III group B streptococci isolated in perinatal infections.Antibiotic resistance patterns of group B streptococcal clinical isolates.Transplacental passage of vancomycin in the ex vivo human perfusion model.Serotypes and genotypes of erythromycin-resistant group B streptococci in Korea.Pharmacokinetics of penicillin g in very-low-birth-weight neonates.Prevention of group B streptococcal infection in newborns. Recommendation statement from the Canadian Task Force on Preventive Health Care.Six-month multicenter study on invasive infections due to group B streptococci in Argentina.Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.Antibiotic resistance patterns in invasive group B streptococcal isolatesAntibiotic susceptibility in neonatal invasive isolates of Streptococcus agalactiae in a 2-year nationwide surveillance study in Germany.Antimicrobial susceptibilities of group B streptococci in New Zealand.
P2860
Q30431534-DB9715C2-5828-4DA2-AD09-D38ABB557F6BQ33552269-FA6FFBEB-C638-4DE9-90EA-0591E1FC6C60Q33555987-AA4653CF-DA4F-45DC-AE47-18351B4DF180Q33883616-2258C22B-2AE6-47C1-8AB2-CD3CA087240BQ33911783-07703DF7-DEB0-49A3-8C85-DEF4CA87C3FEQ33982390-F424E1F5-E13F-44B7-A051-A5982F492722Q33983401-97024224-188B-4E54-BC6E-0A30CDFD9A88Q33983637-3A126FF0-8452-4322-892A-27A87075CD3FQ33983734-A59DB164-9812-480F-B956-793D57C27FB3Q34231603-D9DDAF35-8A48-4F0A-B98D-9080E58B5E8CQ34571597-C9501C80-7437-4F5D-83A9-81FDC4514978Q34735517-62D09DCC-FBE3-4B54-BBD5-AC282939E631Q34822471-3A95A4D7-01DE-4A8D-B78A-A565545A9D8CQ34991272-8864FB8D-DDFA-445F-BB93-D714108BD603Q35115488-7174E0FE-E8BB-4D76-B9E6-5ADB83118BD3Q35547508-EC7A5B33-C827-43AA-ACCE-89201F62956CQ35614542-1976F9EC-7559-4C6E-A786-6202728FCAB7Q35614548-9A5C1306-D186-48B1-A40D-B1218DE0D27BQ35712918-F053BE18-AFC1-42C9-8AF4-7708BEA56FDAQ35840847-367BFD10-5EF5-4869-9CD2-EF857E26982CQ36405807-1375747C-97A0-473D-AEB1-015F5D473634Q36891987-1AC9E4EC-4D01-4D0B-9394-191104222923Q36993479-703A33B5-C1DF-40EF-AB6E-9903DC60EFC4Q37087332-95620755-6BC8-457F-88A6-2D8B9848454BQ37598608-D7DE412D-CBAE-4777-95D2-A0078385656CQ46142033-B9A1A951-AE19-42FD-BECB-06B9BB822458
P2860
Antimicrobial susceptibilities of group B streptococci isolated between 1992 and 1996 from patients with bacteremia or meningitis.
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
name
Antimicrobial susceptibilities ...... with bacteremia or meningitis.
@ast
Antimicrobial susceptibilities ...... with bacteremia or meningitis.
@en
type
label
Antimicrobial susceptibilities ...... with bacteremia or meningitis.
@ast
Antimicrobial susceptibilities ...... with bacteremia or meningitis.
@en
prefLabel
Antimicrobial susceptibilities ...... with bacteremia or meningitis.
@ast
Antimicrobial susceptibilities ...... with bacteremia or meningitis.
@en
P2093
P2860
P356
P1476
Antimicrobial susceptibilities ...... with bacteremia or meningitis
@en
P2093
M E Hickman
M Fernandez
P2860
P304
P356
10.1128/AAC.42.6.1517
P407
P577
1998-06-01T00:00:00Z